Orexo AB (ORX):企業の財務・戦略的SWOT分析

◆英語タイトル:Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15304
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Orexo AB (ORX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company’s commercial product portfolio consists of Abstral, Edluar and Zubsolv. The company employs proprietary drug delivery technologies in the development of its products. It also carries out the industrial-scale production of pharmaceutical products. Orexo works in collaboration with various pharmaceutical companies including, Meda, Kyowa Hakko Kirin, Sentynl Therapeutics, ProStrakan, AstraZeneca and Mundipharma to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jan 30,2019: Orexo: Q4 incl. full year report 2018
Dec 13,2018: Orexo Regains Rights to Zubsolv in all Countries Outside the US
Nov 30,2018: US Court of Appeals Denies Actavis’s Petition for Rehearing Regarding Validity of the Zubsolv Patent
Nov 05,2018: Orexo appoints Joseph DeFeo as CFO
Oct 25,2018: Orexo: Interim Report Q3 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Orexo AB – Key Facts
Orexo AB – Key Employees
Orexo AB – Key Employee Biographies
Orexo AB – Major Products and Services
Orexo AB – History
Orexo AB – Company Statement
Orexo AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Orexo AB – Business Description
Product Category: Abstral
Overview
Performance
Product Category: Edluar
Overview
Performance
Product Category: Zubsolv
Overview
Performance
Geographical Segment: EU
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: US
Performance
R&D Overview
Orexo AB – Corporate Strategy
Orexo AB – SWOT Analysis
SWOT Analysis – Overview
Orexo AB – Strengths
Orexo AB – Weaknesses
Orexo AB – Opportunities
Orexo AB – Threats
Orexo AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Orexo AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 30, 2019: Orexo: Q4 incl. full year report 2018
Nov 30, 2018: US Court of Appeals Denies Actavis’s Petition for Rehearing Regarding Validity of the Zubsolv Patent
Oct 25, 2018: Orexo: Interim Report Q3 2018
Oct 24, 2018: Orexo appoints Joseph DeFeo as new CFO
Oct 08, 2018: Orexo Appoints Nomination Committee and Publishes Financial Calendar 2018/2019
Oct 01, 2018: Orexo internalizes contract Field force in the US to further strengthen the commercial organization
Sep 10, 2018: TOPC : Orexo Wins Appeal Against Actavis on Zubsolv Patent in the US[Newswire : Healthcare-PRN UK]
Jul 11, 2018: Orexo: Interim Report Q2 2018
May 31, 2018: Orexo’s CFO resigns and will leave the company in November 2018
Apr 26, 2018: Orexo – Interim Report Q1 2018
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Orexo AB, Key Facts
Orexo AB, Key Employees
Orexo AB, Key Employee Biographies
Orexo AB, Major Products and Services
Orexo AB, History
Orexo AB, Subsidiaries
Orexo AB, Key Competitors
Orexo AB, Ratios based on current share price
Orexo AB, Annual Ratios
Orexo AB, Annual Ratios (Cont...1)
Orexo AB, Annual Ratios (Cont...2)
Orexo AB, Interim Ratios
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Orexo AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Orexo AB, Performance Chart (2014 - 2018)
Orexo AB, Ratio Charts
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Orexo AB (ORX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Empresas Publicas De Medellin ESP:企業の戦略的SWOT分析
    Empresas Publicas De Medellin ESP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Mizuho Trust & Banking Co Ltd:戦略・SWOT・企業財務分析
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • MediaValet Inc.:戦略・SWOT・企業財務分析
    MediaValet Inc. - Strategy, SWOT and Corporate Finance Report Summary MediaValet Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • PhaseRx Inc (PZRX)-医療機器分野:企業M&A・提携分析
    Summary PhaseRx Inc (PhaseRx), formerly PhaseRx Pharmaceuticals Inc is a healthcare products provider that conducts research and develops RNA nanomedicines for the treatment of orphan diseases. The company discovers and develops drugs based on SMARTT polymer technology, which offers mRNA delivery te …
  • Asahi Group Holdings Ltd:戦略・SWOT・企業財務分析
    Asahi Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Asahi Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • TS Corp (001790):企業の財務・戦略的SWOT分析
    TS Corp (001790) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • U.S. Concrete Inc (USCR):企業の財務・戦略的SWOT分析
    Summary U.S. Concrete Inc (US Concrete) is a construction company that manufactures and markets ready-mixed concrete and aggregates. The company’s aggregate products include crushed stone, sand and gravel used in commercial, industrial and public works. It also provides specialty products such as ra …
  • Toppan Printing Co Ltd:企業の戦略・SWOT・財務情報
    Toppan Printing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Toppan Printing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066)-医療機器分野:企業M&A・提携分析
    Summary Shandong Weigao Group Medical Polymer Company Ltd (Weigao) researches, develops, manufactures and sells disposable medical consumables, orthopedic materials and blood purification products. Its products include infusion sets, needles, blood bags, heart eluting stents, blood sampling products …
  • Visteon Corp (VC):企業の財務・戦略的SWOT分析
    Visteon Corp (VC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Emerson Electric Co (EMR):企業の財務・戦略的SWOT分析
    Emerson Electric Co (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Whatabrands LLC:企業の戦略・SWOT・財務情報
    Whatabrands LLC - Strategy, SWOT and Corporate Finance Report Summary Whatabrands LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Al Mouwasat Medical Services Company (4002):企業の財務・戦略的SWOT分析
    Summary Al Mouwasat Medical Services Company (Mouwasat Medical) is a healthcare service provider that provides health and skincare services. The centre offers services in health care, skin care, and fertility treatment. It provides clinical pharmacy services such as verifying dosages appropriateness …
  • Fluidigm Corp (FLDM)-医療機器分野:企業M&A・提携分析
    Summary Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, ca …
  • Millennium Minerals Limited:企業の戦略・SWOT・財務情報
    Millennium Minerals Limited - Strategy, SWOT and Corporate Finance Report Summary Millennium Minerals Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Toei Animation Co., Ltd. (4816):企業の財務・戦略的SWOT分析
    Toei Animation Co., Ltd. (4816) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Singulus Technologies AG (SNG):電力:M&Aディール及び事業提携情報
    Summary Singulus Technologies AG (Singulus Technologies) is an optical disc production line manufacturer that develops technologies for efficient and resource-conserving production processes. The company offers optical disc solutions such as blu-ray disc, CD, and DVD production equipment. Its solar …
  • Vietnam Electricity-エネルギー分野:企業M&A・提携分析
    Summary Vietnam Electricity (EVN) is an electric utility, which generates, transmits and distributes, and sells energy. It produces power from hydro, coal, oil, and gas sources. The company operates various power plants and electricity generation companies. EVN owns the electricity retailing, transm …
  • Koninklijke Philips N.V. (PHIA)-エネルギー分野:企業M&A・提携分析
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company which focuses on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The company develops and manufactures medical …
  • Moody’s Corporation:企業の戦略・SWOT・財務情報
    Moody's Corporation - Strategy, SWOT and Corporate Finance Report Summary Moody's Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆